Filing Details
- Accession Number:
- 0001179110-14-008677
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-05-16 17:33:52
- Reporting Period:
- 2014-05-14
- Filing Date:
- 2014-05-16
- Accepted Time:
- 2014-05-16 17:33:52
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 815094 | Abiomed Inc | ABMD | Surgical & Medical Instruments & Apparatus (3841) | 042743260 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1399519 | M David Weber | C/O Abiomed, Inc. 22 Cherry Hill Drive Danvers MA 01923 | Chief Operating Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, $.01 Par Value | Acquisiton | 2014-05-14 | 5,000 | $0.00 | 131,907 | No | 4 | A | Direct | |
| Common Stock, $.01 Par Value | Disposition | 2014-05-15 | 1,425 | $20.94 | 130,482 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2014-05-14 | 15,000 | $0.00 | 15,000 | $21.55 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 15,000 | 2015-05-14 | 2024-05-14 | No | 4 | A | Direct |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | $13.88 | 2008-04-23 | 2017-04-23 | 130,000 | 130,000 | Direct |
| Common Stock | Stock Option (right to buy) | $13.80 | 2009-05-23 | 2018-05-23 | 12,000 | 12,000 | Direct |
| Common Stock | Stock Option (right to buy) | $5.86 | 2010-05-28 | 2019-05-28 | 6,500 | 58,500 | Direct |
| Common Stock | Stock Options (right to buy) | $5.86 | 2010-03-31 | 2019-05-28 | 34,500 | 34,500 | Direct |
| Common Stock | Stock Option (right to buy) | $10.03 | 2011-06-03 | 2020-06-03 | 50,000 | 50,000 | Direct |
| Common Stock | Stock Option (right to buy) | $22.44 | 2013-05-22 | 2022-05-22 | 25,000 | 25,000 | Direct |
| Common Stock | Stock Option (Right to Buy) | $23.15 | 2014-05-14 | 2023-05-14 | 23,000 | 23,000 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2017-04-23 | 130,000 | 130,000 | Direct |
| 2018-05-23 | 12,000 | 12,000 | Direct |
| 2019-05-28 | 6,500 | 58,500 | Direct |
| 2019-05-28 | 34,500 | 34,500 | Direct |
| 2020-06-03 | 50,000 | 50,000 | Direct |
| 2022-05-22 | 25,000 | 25,000 | Direct |
| 2023-05-14 | 23,000 | 23,000 | Direct |
Footnotes
- Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2000 Stock Incentive Plan.
- This option becomes exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6.
- Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.
- Sale of common stock pursuant to reporting owner's 10b5-1 plan sold to pay tax obligations upon vesting.
- This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $20.6200 and $21.4000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 14, 2015, May 14, 2016 and May 14, 2017, so long as the reporting person continues to be employed by the issuer on the vesting dates.
- In addition, performance share awards of up to 11,250 restricted units were granted to this reporting person on May 14, 2014. The number of restricted stock units that will become eligible for vesting pursuant to this award will be determined based on the issuer's fiscal 2015 financial performance. One third of the restricted stock units that become eligible for vesting will vest on the date the issuer first publicly announces its financial results for fiscal 2015. The remaining restricted stock units that become eligible for vesting will vest and the underlying shares will be delivered to the reporting person in equal tranches on each of May 14, 2016 and May 14, 2017, in all cases, so long as the reporting person continues to be employed by the issuer on the vesting dates.
- In addition, performance share awards of up to 18,000 restricted units were granted to this reporting person on May 14, 2014. One half of these restricted stock units will vest immediately upon the issuer's achievement of certain regulatory milestones within three years of the date of grant, with the remaining vesting on the first anniversary of such achievement.
- These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
Billionaire Hedge Funds
